Ignite Creation Date:
2025-12-24 @ 10:12 PM
Ignite Modification Date:
2026-01-01 @ 9:13 PM
Study NCT ID:
NCT02752035
Status:
COMPLETED
Last Update Posted:
2025-09-12
First Post:
2016-04-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-18
Completion Date Type:
ACTUAL
First Submit Date:
2016-04-22
First Submit QC Date:
None
Study First Post Date:
2016-04-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2025-07-16
Results First Submit QC Date:
None
Results First Post Date:
2025-09-12
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-03-12
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2025-08-25
Last Update Post Date:
2025-09-12
Last Update Post Date Type:
ESTIMATED